Valproate and spinal muscular atrophy (Review)

Molecular Medicine Reports

Volumn 1, Issue 2, 2008, Pages 161-165

  Natasha, Gemma ^a   Brandom, Kevin G ^a   Young, Elizabeth C ^a   Young, Philip J ^a  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

Spinal muscular atrophy; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID RECEPTOR AFFECTING AGENT; HISTONE DEACETYLASE INHIBITOR; MONOAMINE; NEUROTRANSMITTER; SURVIVAL MOTOR NEURON PROTEIN 2; VALNOCTAMIDE; VALPROIC ACID; VALPROMIDE; VALROCEMIDE;

DISEASE SEVERITY; DRUG MECHANISM; DRUG TARGETING; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HEMATOLOGIC DISEASE; HUMAN; LIVER DISEASE; METABOLIC DISORDER; NEURAL TUBE DEFECT; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SPINAL MUSCULAR ATROPHY; TOXICITY;

EID: 69249098265     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Lefebvre S, Burglen L, Reboullet S, et al: Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80: 155-165, 1995.
2. Lorson CL and Androphy EJ: An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 9: 259-265, 2000.
3. Lorson CL, Hahnen E, Androphy EJ and Wirth B: A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96: 6307-6311, 1999. (Pubitemid 29256661)
4. Monani UR, Lorson CL, Parsons DW, et al: A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 8: 1177-1183, 1999.
5. Lorson CL, Strasswimmer J, Yao JM, et al: SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet 19: 63-66, 1998. (Pubitemid 28242025)
6. Coovert DD, Le TT, McAndrew PE, et al: The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 6: 1205-1214, 1997.
7. Lefebvre S, Burlet P, Liu Q, et al: Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16: 265-269, 1997. (Pubitemid 27280210)
8. Monani UR, Coovert DD and Burghes AH: Animal models of spinal muscular atrophy. Hum Mol Genet 9: 2451-2457, 2000. (Pubitemid 30814632)
9. Monani UR, Sendtner M, Coovert DD, et al: The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 9: 333-339, 2000. (Pubitemid 30098725)
10. Wirth B, Brichta L, Schrank B, et al: Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 119: 422-428, 2006.
11. Avila AM, Burnett BG, Taye AA, et al: Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 117: 659-671, 2007.
12. Brichta L, Hofmann Y, Hahnen E, et al: Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12: 2481-2489, 2003. (Pubitemid 37220412)
13. Hahnen E, Eyüpoglu IY, Brichta L, et al: In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 98: 193-202, 2006.
14. Kernochan LE, Russo ML, Woodling NS, et al: The role of histone acetylation in SMN gene expression. Hum Mol Genet 14: 1171-1182, 2005. (Pubitemid 40613906)
15. Riessland M, Brichta L, Hahnen E and Wirth B: The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet 120: 101-110, 2006.
16. Eadie MJ: Could valerian have been the first anticonvulsant? Epilepsia 45: 1338-1343, 2004.
17. Eadie MJ, Heazlewood V, McKauge L and Tyrer JH: Steady-state valproate pharmacokinetics during long term therapy. Clin Exp Neurol 19: 183-191, 1983.
18. Eadie MJ, Tyrer JH, Smith GA and McKauge L: Pharmacokinetics of drugs used for petit mal 'absence' epilepsy. Clin Exp Neurol 14: 172-183, 1977.
19. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA and Klein PS: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741, 2001. (Pubitemid 37384288)
20. Shpargel KB and Matera AG: Gemin proteins are required for efficient assembly of Sm-class ribonucleoproteins. Proc Natl Acad Sci USA 102: 17372-17377, 2005.
21. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E and Tomson T: Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 61: 1-48, 2004. (Pubitemid 39296697)
22. Johannessen CU and Johannessen SI: Valproate: past, present, and future. CNS Drug Rev 9: 199-216, 2003.
23. Johannessen SI and Ben-Menachem E: Management of focal-onset seizures: an update on drug treatment. Drugs 66: 1701-1725, 2006. (Pubitemid 44427434)
24. Johannessen CU: Mechanisms of action of valproate: a commentatory. Neurochem Int 37: 103-110, 2000.
25. Perucca E and Johannessen SI: The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? Epileptic Disord 5 (Suppl 1): 17-26, 2003.
26. Johannessen SI and Tomson T: Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 45: 1061-1075, 2006.
27. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P and Perucca E: Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 51: 31-71, 2002. (Pubitemid 35283878)
28. Hassel B, Iversen EG, Gjerstad L and Tauboll E: Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J Neurochem 77: 1285-1292, 2001. (Pubitemid 32523681)
29. Löscher W: In vivo administration of valproate reduces the nerve terminal (synaptosomal) activity of GABA amino-transferase in discrete brain areas of rats. Neurosci Lett 160: 177-180, 1993.
30. Löscher W: Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem Res 18: 485-502, 1993.
31. Löscher W and Hönack D: Effects of the competitive NMDA receptor antagonist, CGP 37849, on anticonvulsant activity and adverse effects of valproate in amygdala-kindled rats. Eur J Pharmacol 234: 237-245, 1993. (Pubitemid 23103446)
32. Valin A, Voltz C, Naquet R and Lloyd KG: Effects of pharmacological manipulation on neurotransmitter and other amino acid levels in the CSF of the Senegalese baboon Papio papio. Brain Res 538: 15-23, 1991.
33. Ahmad AM, Douglas Boudinot F, Barr WH, Reed RC and Garnett WR: The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric-coated and extended release divalproex sodium formulations. Biopharm Drug Dispos 26: 417-425, 2005.
34. Baf MH, Subhash MN, Lakshmana KM and Rao BS: Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem Int 24: 67-72, 1994. (Pubitemid 24034160)
35. Narita N, Kato M, Tazoe M, Miyazaki K, Narita M and Okado N: Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. Pediatr Res 52: 576-579, 2002.
36. Owens MJ and Nemeroff CB: Pharmacology of valproate. Psychopharmacol Bull 37 (Suppl 2): 17-24, 2003.
37. Vriend JP and Alexiuk NA: Effects of valproate on amino acid and monoamine concentrations in striatum of audiogenic seizure-prone Balb/c mice. Mol Chem Neuropathol 27: 307-324, 1996.
38. Yamamoto R, Yanagita T, Kobayashi H, Yokoo H and Wada A: Up-regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: activation of calcium channel and catecholamine secretion in adrenal chromaffin cells. J Neurochem 68: 1655-1662, 1997. (Pubitemid 27133075)
39. Slater GE and Johnston D: Sodium valproate increases potassium conductance in Aplysia neurons. Epilepsia 19: 379-384, 1978.
40. Tsai LK, Tsai MS, Lin TB, Hwu WL and Li H: Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis 24: 286-295, 2006. (Pubitemid 44572748)
41. Di Daniel E, Cheng L, Maycox PR and Mudge AW: The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters. Mol Cell Neurosci 32: 27-36, 2006. (Pubitemid 43868094)
42. Morland C, Boldingh KA, Iversen EG and Hassel B: Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high-affinity glutamate uptake. J Cereb Blood Flow Metab 24: 1226-1234, 2004. (Pubitemid 39482484)
43. Rekling JC: Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation. Neurosci Lett 335: 167-170, 2003.
44. Janssen F, Rambeck B and Schnabel R: Acute valproate intoxication with fatal outcome in an infant. Neuropediatrics 16: 235-238, 1985. (Pubitemid 16199262)
45. Van Bergeijk J, Haastert K, Grothe C and Claus P: Valproic acid promotes neurite outgrowth in PC12 cells independent from regulation of the survival of motoneuron protein. Chem Biol Drug Des 67: 244-247, 2006.
46. Van Bergeijk J, Rydel-Könecke K, Grothe C and Claus P: The spinal muscular atrophy gene product regulates neurite outgrowth: importance of the C terminus. FASEB J 21: 1492-1502, 2007. (Pubitemid 46684851)
47. Sugai F, Yamamoto Y, Miyaguchi K, et al: Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 20: 3179-3183, 2004. (Pubitemid 40007312)